New advances made in the treatment of lung cancer

New advances made in the treatment of lung cancer. Clinical trials showed prolonged progression-free survival with checkpoint inhibitor therapy. The phase III PACIFIC trial demonstrated an overall survival benefit for the selective programmed cell death ligand 1 (PD-L1) checkpoint inhibitor durvalumab (Imfinzi) vs placebo in patients with unresectable stage III NSCLC

 

Durvalumab Improves Overall Survival in Unresectable Stage III NSCLC -Screen

 

More Information: http://www.ascopost.com/issues/october-25-2018/durvalumab-improves-overall-survival-in-unresectable-stage-iii-nsclc/?fbclid=IwAR0cdr2zqOZIVnHRcLnurXjxhj92SigqJCPFZFC57N8J9dRBxcpjRq58J5A